iMBC Co.,Ltd. (KOSDAQ:052220)

Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	44,183	45,443	46,304	47,460	46,833	43,732
Revenue Growth (YoY)	-5.04%	-1.86%	-2.44%	1.34%	7.09%	-15.17%
Cost of Revenue	24.27	19.48	15.11	29.28	20.84	49.02
Gross Profit	44,159	45,423	46,289	47,431	46,812	43,683
Selling, General & Admin	40,341	41,323	42,252	42,685	41,684	40,281
Other Operating Expenses	74.83	73.86	75.35	67.85	44.93	38.96
Operating Expenses	43,872	44,789	45,132	45,299	44,471	42,564
Operating Income	287.25	634.53	1,157	2,132	2,341	1,119
Interest Expense	-85.83	-95.53	-245.75	-73.76	-89.74	-94.96
Interest & Investment Income	1,643	1,584	1,464	1,363	1,131	1,122
Earnings From Equity Investments	25.3	25.3	-139.55	-340.04	-587.31	264.41
Currency Exchange Gain (Loss)	0.45	17.9	-20.76	-22.44	-5.75	-33.9
Other Non Operating Income (Expenses)	264.84	277.29	424.29	288.9	244.01	-184.44
EBT Excluding Unusual Items	2,135	2,444	2,639	3,348	3,034	2,192
Gain (Loss) on Sale of Investments	97.43	131	497.28	-	5.22	102.22
Gain (Loss) on Sale of Assets	116.03	116.03	2.67	84.68	407.51	-14.31
Asset Writedown	-123.88	-123.88	-574.45	-891.34	-530.4	-562.52
Pretax Income	2,224	2,567	2,565	2,541	2,916	1,717
Income Tax Expense	459.81	554.25	428.51	755.07	1,572	417.76
Earnings From Continuing Operations	1,765	2,013	2,136	1,786	1,344	1,300
Minority Interest in Earnings	-21.25	-54.96	-57.81	-116.41	-236.13	-207.93
Net Income	1,743	1,958	2,079	1,669	1,108	1,092
Net Income to Common	1,743	1,958	2,079	1,669	1,108	1,092
Net Income Growth	37.54%	-5.81%	24.52%	50.73%	1.46%	-48.89%
Shares Outstanding (Basic)	23	23	23	23	23	23
Shares Outstanding (Diluted)	23	23	23	23	23	23
Shares Change (YoY)	-2.30%	-	-	-	-	-
EPS (Basic)	77.15	85.12	90.38	72.58	48.15	47.46
EPS (Diluted)	77.15	85.12	90.38	72.58	48.15	47.46
EPS Growth	40.77%	-5.81%	24.52%	50.73%	1.46%	-48.89%
Free Cash Flow	10,873	6,575	-4,944	3,810	3,842	1,542
Free Cash Flow Per Share	481.11	285.87	-214.97	165.67	167.03	67.04
Gross Margin	99.94%	99.96%	99.97%	99.94%	99.95%	99.89%
Operating Margin	0.65%	1.40%	2.50%	4.49%	5.00%	2.56%
Profit Margin	3.95%	4.31%	4.49%	3.52%	2.37%	2.50%
Free Cash Flow Margin	24.61%	14.47%	-10.68%	8.03%	8.20%	3.53%
EBITDA	3,762	4,036	3,942	4,262	5,007	3,349
EBITDA Margin	8.51%	8.88%	8.51%	8.98%	10.69%	7.66%
D&A For EBITDA	3,474	3,402	2,786	2,130	2,666	2,230
EBIT	287.25	634.53	1,157	2,132	2,341	1,119
EBIT Margin	0.65%	1.40%	2.50%	4.49%	5.00%	2.56%
Effective Tax Rate	20.67%	21.59%	16.71%	29.72%	53.92%	24.33%
Advertising Expenses	-	236.2	250.31	306.37	457.99	509.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.